Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 14/20 | 0.68 |
| ▸ | BRAF | P15056 | 2/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936931 | 0.87 | RAF1 (0.68) | RAF1BRAFMAPK14KDRRET | |
| SCHEMBL938799 | 0.80 | RAF1 (0.51) | RAF1BRAFKDR | |
| SCHEMBL937281 | 0.80 | RAF1 (0.57) | RAF1BRAFMAPK14KDRRET | |
| SCHEMBL16621336 | 0.80 | RAF1 (0.84) | RAF1BRAFMAPK14KDR | |
| SCHEMBL937760 | 0.78 | RAF1 (0.68) | RAF1BRAFMAPK14KDRRET | |
| SCHEMBL938360 | 0.74 | RAF1 (0.62) | RAF1BRAFMAPK14KDR | |
| SCHEMBL16628039 | 0.73 | MAPK14 (0.71) | RAF1BRAFMAPK14KDR | |
| SCHEMBL13556629 | 0.73 | RAF1 (0.72) | RAF1BRAFMAPK14KDRRET | |
| SCHEMBL13529088 | 0.73 | RAF1 (0.70) | RAF1BRAFMAPK14KDRRET | |
| SCHEMBL16506752 | 0.72 | BRAF (0.62) | RAF1BRAFMAPK14KDRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | claimed |
| EP-1478358-B1 | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis | BAYER HEALTHCARE LLC (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-1636585-B2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2289515-A2 | Combinations comprising a diaryl urea and an interferon | Bayer HealthCare LLC (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | DUMAS JACQUES | 2011-01-20 | — | — | US | disclosed |
| US-7838541-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | RAF1 867/4885BRAF 487/4885MAPK14 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.